You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 11, 2025

Drug Price Trends for ALYQ


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for ALYQ

Average Pharmacy Cost for ALYQ

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
ALYQ 20 MG TABLET 00093-3334-06 0.26718 EACH 2025-01-22
ALYQ 20 MG TABLET 00480-9277-06 0.26718 EACH 2025-01-22
ALYQ 20 MG TABLET 00093-3334-06 0.26580 EACH 2024-12-18
ALYQ 20 MG TABLET 00480-9277-06 0.26580 EACH 2024-12-18
ALYQ 20 MG TABLET 00093-3334-06 0.28688 EACH 2024-11-20
ALYQ 20 MG TABLET 00480-9277-06 0.28688 EACH 2024-11-20
ALYQ 20 MG TABLET 00093-3334-06 0.26748 EACH 2024-10-23
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for ALYQ (Tadalafil)

Introduction to ALYQ

ALYQ, a generic version of ADCIRCA (tadalafil), is a phosphodiesterase 5 (PDE5) inhibitor primarily used for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability. It was launched by Teva Pharmaceutical Industries Ltd. in the United States in 2019[4].

Market Size and Growth

The launch of ALYQ is part of a broader trend in the pharmaceutical industry where generic versions of popular drugs are becoming increasingly available. The Erectile Dysfunction Treatment Drugs Market, which also includes PDE5 inhibitors like tadalafil, is expected to grow significantly. For instance, the Erectile Dysfunction Treatment Drugs Market was valued at USD 3.31 billion in 2023 and is projected to reach USD 5.97 billion by 2032, with a compound annual growth rate (CAGR) of 6.84% from 2024 to 2032[1].

Pricing and Affordability

The cost of ALYQ is substantial but competitive with its branded counterpart. As of the latest data, the cost for ALYQ 20 mg oral tablets is around $1,197 for a supply of 60 tablets, which translates to approximately $19.96 per unit. This pricing is based on cash-paying customers and may vary depending on the pharmacy and any available discounts or insurance plans[2].

Market Drivers

Several factors drive the market for ALYQ and similar generic medications:

  • Accessibility and Awareness: Increased public awareness about treatment options for conditions like PAH and erectile dysfunction boosts sales. Educational campaigns and the wider availability of medications through online providers and hospital pharmacies contribute to this growth[1].
  • Generic Competition: The introduction of generic versions like ALYQ reduces the cost barrier for patients, making treatments more affordable and accessible. This competition also pressures branded drug manufacturers to adjust their pricing strategies[4].

Market Restraints

Despite the positive trends, there are several challenges that could impact the market for ALYQ:

  • Patent Cliff: The expiration of patents on major medications can lead to increased competition from generics, which may erode market share for branded drugs. However, for ALYQ, the generic launch itself is a response to the patent expiration of the branded version[1][3].
  • Regulatory and Competitive Pressures: Pharmaceutical companies face regulatory challenges and competition from other generic and branded products. Efforts to limit the use of generics through legislation and regulations can also impact market dynamics[4].

Regional Analysis

North America, particularly the United States, is a significant market for ALYQ. Teva's launch of ALYQ in the U.S. capitalizes on the large patient pool and the established healthcare infrastructure in the region. The U.S. market is crucial for generic drug manufacturers due to its size and the high demand for affordable treatment options[1].

Future Price Projections

Given the competitive nature of the generic drug market, prices for ALYQ are likely to remain competitive or even decrease over time. Here are some factors that could influence future price projections:

  • Generic Competition: As more generic versions of tadalafil enter the market, prices are expected to decrease due to increased competition[4].
  • Regulatory Changes: Initiatives like the Medicare price negotiation program announced by the Biden-Harris administration could lead to lower prices for prescription drugs, including generics like ALYQ, as part of broader efforts to reduce healthcare costs[5].

Key Takeaways

  • Market Growth: The market for PDE5 inhibitors, including ALYQ, is expected to grow with a CAGR of 6.84% from 2024 to 2032.
  • Pricing: The current cost of ALYQ is around $1,197 for a 60-tablet supply, with potential for price reductions due to generic competition.
  • Accessibility: Increased awareness and availability of generic medications are driving market growth.
  • Regulatory Impact: Future price negotiations and regulatory changes could further reduce the cost of ALYQ and similar medications.

FAQs

Q: What is ALYQ used for? A: ALYQ (tadalafil) is primarily used for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability.

Q: How much does ALYQ cost? A: The cost for ALYQ 20 mg oral tablets is around $1,197 for a supply of 60 tablets, which is approximately $19.96 per unit.

Q: Who launched ALYQ in the U.S.? A: ALYQ was launched by Teva Pharmaceutical Industries Ltd. in the United States in 2019.

Q: What are the key drivers of the market for ALYQ? A: Key drivers include increased accessibility and awareness of treatment options, as well as the availability of generic versions.

Q: How might future regulatory changes impact the price of ALYQ? A: Regulatory changes, such as Medicare price negotiations, could lead to lower prices for ALYQ and other prescription drugs.

Sources

  1. Erectile Dysfunction Treatment Drugs Market Size, Share 2032 - SNS Insider
  2. Alyq Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com
  3. NSCLC MARKET - Global Drug Forecast & Market Analysis to 2025 - Drug Development Technology
  4. Teva Announces Launch of ALYQ™ (Tadalafil Tablets USP), a Generic Version of ADCIRCA® in the United States - BioSpace
  5. Biden-Harris Administration Announces New, Lower Prices for First Ten Drugs Selected for Medicare Price Negotiation - The White House

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.